Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the acf domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/vhosts/viewstream-media.com/cri.viewstream-media.com/wp-includes/functions.php on line 6131

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/vhosts/viewstream-media.com/cri.viewstream-media.com/wp-includes/functions.php on line 6131

Notice: Undefined offset: 0 in /var/www/vhosts/viewstream-media.com/cri.viewstream-media.com/wp-content/themes/cri/single.php on line 10

Notice: Trying to get property 'name' of non-object in /var/www/vhosts/viewstream-media.com/cri.viewstream-media.com/wp-content/themes/cri/single.php on line 10
What Patients Need to Know About Lung Cancer Immunotherapy
stdClass Object ( [getLoginUrlResponse] => stdClass Object ( [JSESSIONID] => C6A2166AE157CAF4A6CBB8A285413A2F.app30109b [routing_id] => 00000000.app30109b [url] => https://give.cancerresearch.org/site/CRConsAPI;jsessionid=00000000.app30109b?NONCE_TOKEN=DCFB4DB03F1BD354CA5B60AC4C81156F [token] => JiSWAQqgpsq7w6lhJ8bpIXEcgLo4HKlTY8JuBfIW6-3mF_QwJKVY66IpAUtH1-b5s5wL3TO8QNvg3GLQk55UkEBYGYs35eN7B7csBMg ) ) test

Immune to Cancer: The CRI Blog

Subscribe

Share

What Patients Need to Know About Lung Cancer Immunotherapy

Michelle Liew

Once thought of as a type of cancer that was unable to provoke an immune response, lung cancer has recently emerged as an exciting new target of immune-based therapies. The first immunotherapy approved by the FDA in the treatment of lung cancer in March 2015 and recent clinical trial developments are giving patients, like Maureen, new treatment options with impressive results.

On Friday, August 21, at 2:00 p.m. EDT, Julie Brahmer, M.D., associate professor of oncology and interim director of the Johns Hopkins Sidney Kimmel Cancer Center, will discuss the latest research and current immunotherapies for patients with lung cancer.

Dr. Brahmer’s research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. She received her M.D. from the University of Nebraska Medical Center and her residency in internal medicine at The University of Utah. She completed her fellowship in oncology at the Johns Hopkins University School of Medicine and is also certified in medical oncology from the American Board of Internal Medicine. Dr. Brahmer is the Johns Hopkins principal investigator on the SU2C-ACS Lung Cancer “Dream Team” grant.

This 45-minute webinar, which is generously supported by Regeneron and a part of the Cancer Research Institute's Breakthrough in Cancer Immunotherapy webinar series, is free to the public, but seats are limited, so register now.

Register Today

Julie Brahmer, M.D.
Immunotherapy for Lung Cancer: What Patients Need to Know
Friday, August 21, 2015, at 2:00 p.m. EDT

Read more:

This site is registered on wpml.org as a development site.